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Esmolol reduces anesthetic requirements
thereby facilitating early extubation; a
prospective controlled study in patients
undergoing intracranial surgery
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Abstract
Background: Adequate cerebral perfusion pressure with quick and smooth emergence from anesthesia is a major
concern of the neuroanesthesiologist. Anesthesia techniques that minimize anesthetic requirements and their
effects may be beneficial. Esmolol, a short acting hyperselective β-adrenergic blocker is effective in blunting
adrenergic response to several perioperative stimuli and so it might interfere in the effect of the anesthetic drugs
on the brain. This study was designed to investigate the effect of esmolol on the consumption of propofol and
sevoflurane in patients undergoing craniotomy.
Method: Forty-two patients that underwent craniotomy for aneurysm clipping or tumour dissection were randomly
divided in two groups (four subgroups). Anesthesia was induced with propofol, fentanyl and a single dose of
cis-atracurium, followed by continuous infusion of remifentanil and either propofol or sevoflurane. Patients in
the esmolol group received 500 mcg/kg of esmolol bolus 10 min before induction of anesthesia, followed by
additional 200 mcg/kg/min of esmolol. Monitoring of the depth of anesthesia was also performed using the
Bispectral Index-BIS and cardiac output. The inspired concentration of sevoflurane and the infusion rate of propofol
were adjusted in order to maintain a BIS value between 40–50. Intraoperative emergence was detected by the
elevation of BIS value, HR or MAP.
Results: The initial and the intraoperative doses of propofol and sevoflurane were 18–50 mcg/kg/min and 0.2–0.5
MAC respectively in the esmolol group, whereas in the control group they where 100–150 mcg/kg/ and 0.9–2.0
MAC respectively (p = 0.000 for both groups). All procedures were anesthesiologically uneventful with no episodes of
intraoperative emerge.
Conclusions: Esmolol is effective not only in attenuating intraoperative hemodynamic changes related to sympathetic
overdrive but also in minimizing significant propofol and sevoflurane requirements without compromising the
hemodynamic status.
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Introduction
Neurosurgical procedures result in a significant release of
adrenaline requiring large amounts of anesthetics and anal-
gesics. However all agents used in neurosurgery should
have minimal effect on brain function, not interfere with
intraoperative neuromonitoring, and allow for a quick and
smooth extubation and recovery. Rapid emergence from
anesthesia after tumor dissection or aneurysm clipping is
essential for early detection of possible neurological impair-
ment due to hematoma formation, edema or vasospasm
and ischemia. In addition, early recovery and extubation is
associated with fewer metabolic and cardiovascular changes
than a 2-hour delayed recovery [1].
Anesthesia with either propofol or sevoflurane com-
bined with a short acting opioid, like remifentanil, is the
preferred pharmacological approach in neuroanesthesia.
Propofol and sevoflurane have a quite similar recovery
time and neuroprotective effect but still controversy
exists regarding the best choice of anesthetics for the
neurosurgical patient [2, 3]. Although propofol is an ap-
propriate component of total intravenous neuroanesthe-
sia, in prolonged neurosurgical cases there is always the
risk of delayed awakening. On the other hand, the use of
sevoflurane in neurosurgery is still under consideration due
to its ability to provoke vasodilation, cerebral hyperemia
and increase intracranial pressure (ICP) even in the
subanesthetic dose of 0.4 MAC (minimum alveolar con-
centration) [1, 4–6]. Investigators have reported signifi-
cantly high doses of propofol (75–200 mcg/kg/min) and
sevoflurane (2.5 MAC) intraoperatively during craniotomy
maintaining a BIS (Bispectral Index) value of 40–50,
which might delay the recovery time [3, 7–11]. These facts
limit the use of both these anesthetic agents.
Esmolol is an ultra-short acting, cardioselective β1-
adrenergic receptor antagonist that is effective in blunting
sympathetic overdrive to several perioperative stimuli,
including laryngoscopy with intubation, intraoperative
events, emergence, and extubation and can be used as an
alternative to opioids for maintaining hemodynamic and
BIS stability during general anesthesia [12]. Esmolol en-
hances the analgesic effect of opioids but has no analgesic
effect when administered alone [13, 14]. As a β1-adrener-
gic blocking agent, esmolol is not a cerebral vasodilator
and has no significant effect on ICP [15, 16]. Studies
evaluating the interaction between β-adrenoceptor antag-
onists and anesthetics on BIS have concluded that esmolol
minimizes the dose of propofol required for intubation
[12, 17]. Our study investigates the effect of esmolol on in-
traoperative requirements of propofol and sevoflurane in
patients undergoing craniotomy.
Methods
The local research ethics committee (Scientific and ethics
committee of G.Papanikolaou Hospital) approved the
study and written informed consent was obtained from all
patients. We included in the study ASA I-II patients, aged
from 18 until 75 years, scheduled for resection of brain
tumor or aneurysm clipping under general anesthesia.
Exclusion criteria included the presence of one or more of
the following: ASA > II, Body Mass Index (BMI) > 30, indi-
cation for rapid sequence induction, contraindication to
β-blocker administration, atrial fibrillation, Glasgow Coma
Scale (GCS) < 15, history of drug abuse, preoperative
aphasia, neurologic deficit or preoperatively foreseen de-
layed extubation.
The patients were randomly divided in two groups; the
esmolol group and the control group. Patients in the con-
trol group were further divided in two subgroups: control-
propofol and control-sevoflurane. Similarly, patients in the
esmolol group were further divided in two subgroups:
esmolol-propofol and esmolol-sevoflurane. The method
used for randomization was simple randomization, similar
to repeated fair coin-tossing. This method was used also
for randomly allocating TIVA vs sevoflurane too.
Before induction in anesthesia standard monitoring
(electrocardiogram of five leads-ECG, noninvasive arterial
blood pressure and pulse oximeter probe) was placed.
Peripheral vein access was established and an isotonic crys-
talloid solution 10 ml/kg before induction and 5 ml/kg/h
intraoperatively was infused. All patients had a 20G cath-
eter inserted in the radial artery for invasive monitoring of
blood pressure and cardiac output (CO) using arterial
pulse contour analysis. Cardiac output was calculated using
the FloTrac™ sensor kit connected to the arterial line and
to the Vigileo™ monitor programmed with the 3.02 version
(Edwards Lifesciences 2009, Thessaloniki, GR) of the soft-
ware for this device. Patient data (age, gender, body weight,
and height) were entered and after checking the arterial
line waveform fidelity, the system was zeroed and CO
measurement was initiated.
A BIS sensor (Aspect Medical System, Inc, GR) was
placed in the frontal area with consideration for the loca-
tion of the surgical incision. Regional brain hemoglobin
oxygen saturation (rSO2) was also monitored using near-
infrared spectroscopy. Immediately before induction of
anesthesia, radiolucent Adult Somasensor oximetry strips
were applied bilaterally to the forehead at standard posi-
tions relative to the midline. Consideration was also given
to the site of craniotomy. The somasensors were con-
nected to an INVOS™ cerebral oximeter, Model 4100
(Somanetics Corp, Covidient, Greece), which provides
real-time numerical rSO2 values for bilateral frontal cortex.
An initial baseline measurement of rSO2 was performed
bilaterally by taking the mean of readings of the last 10
min before intubation. Intraoperative normothermia was
actively maintained with a forced airwarming blanket.
Esmolol group patients received 500 mcg/kg of esmo-
lol 10 min before the induction in anesthesia and for a
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period of 4 min followed by continuous infusion of 200
mcg/kg/min. General anesthesia was induced with propo-
fol (2 mg/kg) and fentanyl (2mcg/kg). Intubation of the
trachea was facilitated by cis-atracurium (0.15 mg/kg)
and ventilation was adjusted to an end-tidal-carbon di-
oxide (EtCO2) tension of 30–35 mmHg in 50 % O2/air.
Anesthesia was maintained using remifentanil (0.2
mcg/kg/min) and either propofol or sevoflurane. The
inspired concentration of sevoflurane and the infusion
rate of propofol were adjusted in order to maintain BIS
values between 40–50. Intraoperative emergence was
detected by elevation of BIS value, HR or MAP. After
extubation, patients were asked if they had experience
episodes of recall. The use of neuromuscular block was
avoided after intubation. At dura closure all patients re-
ceived paracetamol 1gr. Immediately before the discon-
tinuation of remifentanil, all patients received 1 mcg/kg
of fentanyl. Propofol or sevoflurane and remifentanil
were discontinued after skin closure while the adminis-
tration of esmolol was continued for an additional 30
min following extubation. The dose of esmolol in the
esmolol group was reduced in cases of bradycardia
(heart rate-HR < 40) and in cases where mean arterial
pressure-MAP < 50 mmHg. Patients in the control
group, who did not receive esmolol, were transferred to
the intensive care unit (ICU) where they were extu-
bated in the following hours. This decision was made
because it was considered safer for the patients not to
be extubated immediately after the end of the proced-
ure in order to avoid any increase of blood pressure,
considering that they had not received β-blocker for
sympathetic stimulus control.
Study endpoints
Parameters recorded were operative time, duration of
anesthesia (time from induction till discontinuing of
remifentanil-propofol/sevoflurane), orientation time and
extubation time. Orientation time was defined as the time
from discontinuation of all anesthetic agents until the time
the patient opened his eyes and performed specific move-
ments. Extubation time was defined as the time from drug
discontinuation to extubation. The time to reach an
Aldrete score of at least 9 after tracheal extubation was
also recorded. The Aldrete scoring system is widely
accepted in order to assess the physical status of patients
recovering from anesthesia based on a score of five criteria
(mobility-able to move 4 extremities on command,
respiration-able to breathe deeply and cough, oxygenation-
O2 saturation on room air > 92 %, cardiovascular stability-
MAP stable and consciousness-fully awake) [18].
Statistics
Data were expressed as mean ± SD. Differences in cat-
egorical data were evaluated using the student t test. A
beta error level of 20 % or statistical power of 80 % and
a α-level of 0.05 was used to calculate the sample size of
this study. A value of p < 0.05 was considered to repre-
sent statistical significance.
Results
A total of 42 patients (male/female: 23/19, mean age
53.3 ± 17.24) were enrolled. There were no significant
differences between the two groups in regard to their
demographics, duration of anesthesia or type of surgery
(Table 1). All the patients enrolled completed the study.
In the control-propofol group (11 patients), propofol in-
fusion started at rates ranging from 100 to150 μcg/kg/min
(134 ± 12.9mcg/Kg/min) and the infusion rate for each pa-
tient remained quite stable throughout the procedure.
Conversely, in the esmolol-propofol group (11 patients),
propofol was initiated at 40mcg/kg/min in all patients and
was reduced to 18-35 μcg/kg/min (25.83 ± 9.32 mcg/kg/
min) during the procedure (p = 0.000) [Fig. 1]. In the
control-sevoflurane group (10 patients), sevoflurane’s
MAC was initiated at 0.9 to 2 MAC (1.49 ± 0.288) and
remained quite stable throughout the procedure with no
significant fluctuation in any patient. Conversely, in the
esmolol-sevoflurane group (10 patients) the initial MAC
of sevoflurane was 0.5 MAC for all patients and was ad-
justed at 0.2–0.3 MAC (0.31 ± 0.13) during the operation
(p = 0.000) [Fig. 2]. It should be noted that BIS values were
comparable between the control and the esmolol group
considering that BIS values cannot be absolutely stable.
We adjusted propofol infusion rate and inspired concen-
tration of sevoflurane in order to maintain a BIS between
40–50 throughout the procedure.









Body weight (kg) 76.00 ± 10.86 82.4 ± 16.62 >0.05 77.7 ± 14.13
Sex (M/F) 12/9 11/10 >0.05 23/19
ASA (I/II) 11/10 9/12 >0.05 20/22
Operation
Tumor dissection 15 15 30
Aneurysm clipping 6 6 12
Operative time
(min)
267.4 ± 87.52 234.4 ± 74.06 >0.05 241.4 ± 82.034
Anesthesia duration
(min)
345.2 ± 51.08 303.8 ± 84.17 >0.05 338.0 ± 91.54
Orientation time
(min)
- 8.4 ± 3.88
Extubation time
(min)
- 15.6 ± 6.98
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All patients in the esmolol group were successfully extu-
bated with excellent neurological outcomes, coinciding
with the data obtained from the intraoperative clinical
data of the patient, the regional brain saturation monitor-
ing and the macroscopic estimation of the condition of
the cerebral tissue. In one patient in the esmolol group
there was extensive bleeding during tumor dissection
resulting in an hemoglobin drop from 12.3 to 9.8 mg/dl
without however any significant change in cardiac output.
However, the value of the right rSO2 revealed desaturation
26 %, even though the hemoglobin at that moment was
not very low (Fig. 3). The patient was transfused with two
packs of red blood cell (600ml) and the value of rSO2
returned to normal. The patient was successfully extu-
bated 7 min after the end of the operation.
In the esmolol group, orientation and extubation times
were 8.81 ± 4.69 min and 14.4 ± 6.84 min respectively for
the propofol subgroup and 7.57 ± 2.82 min and 14.1 ± 6.99
min respectively for the sevoflurane subgroup. There were
no significant differences between the two subgroups
in orientation times (p = 0.553) and extubation times
(p = 0.949). However, there was a trend towards sevo-
flurane achieving a better and more rapid emerge, al-
though orientation times did not significantly differ
between the propofol and sevoflurane group. The
Aldrete score criteria were reached before extubation,
so the actual time of the Aldrete score of at least 9
was 0 min for all patients in the esmolol group.
All patients in the esmolol group were fully conscious
with no hypoxia after extubation. No patient experienced
Fig. 1 Intraoperative fluctuations of propofol in the control (top of the picture) and the esmolol group (bottom of the picture). Each patient is
indicated with a different color. Initial infusion rate of propofol is higher in the control group compared to the esmolol group. Also, infusion rate
of propofol at each time point was much lower for the esmolol group than for the control group. Mean value of propofol in control group was
134 ± 12.9mcg/Kg/min, where in the esmolol group was 25.83 ± 9.32 mcg/kg/min during the procedure
Fig. 2 Intraoperative fluctuations of sevoflurane in the control (top of the picture) and the esmolol group (bottom of the picture). Each patient is
indicated with a different color. Initial MAC of sevoflurane is higher in the control group compared to the esmolol group. Also MAC of sevoflurane at
each time point was much lower for the esmolol group than the control group. Mean value of sevoflurane in control group was 1.49 ± 0.288 MAC
MAC, where in the esmolol group was 0.31 ± 0.13MAC during the procedure
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hypertension at the time of extubation or during the early
postoperative period after the discontinuation of esmolol.
Hypertension defined as an increase in SBP > 20 % of
the baseline.
There was only one case of postoperative shivering.
There was not noticed any episode of intraoperative
emerge, that could be attributed to low dose of sevoflur-
ane and propofol. This was in agreement also with the
values of BIS. Moreover, none of the patients reported
any episode of recall after when they were asked at the
first postoperative day.
The esmolol regimen used in the present study did
not have any severe hemodynamic effect during induc-
tion or maintenance of anesthesia. Predosing with esmo-
lol 10 min before induction in anesthesia did not affect
the BIS index value. There was no episode of bradycardia
or persistent hypotension requiring intervention. Cardiac
output did not decrease significantly even though MAP
and HR were decreased. The esmolol group showed lower
overall HR than the control group. Heart rate during
tracheal intubation, skin incision, and tracheal extubation
fluctuated less in the esmolol group. The MAP and HR
variations during anesthesia are depicted in Figs. 4 and 5,
respectively. There was no significant difference in HR
and MAP between the control and esmolol group before
induction in anesthesia. However after administration of
esmolol, MAP and HR was significant different; from be-
ginning of infusion until the first postoperative period,
mean MAP at the control group was 83.8 ± 4.46mmHg
when for the same period at the esmolol group was 78.5 ±
4.7mmHg (p = 0.003). Also, for the same period, mean HR
at the control group was 72.2 ± 4.99/min when at the
esmolol group was 65.2 ± 4.45/min (p = 0.000).
Discussion
One of the major challenges of neuroanesthesia is the
ability to provide effective intraoperative analgesia and
anesthesia, perioperative hemodynamic stability and
smooth and early extubation. Our study showed that
esmolol significantly decreased the consumption of
Fig. 3 Desaturation of regional cerebral oxygenation during craniotomy. The blue arrow indicates the period of desaturation
Fig. 4 Mean arterial pressure (MAP) fluctuation regarding perioperative time in the control and esmolol group
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anesthetics (propofol and sevoflurane) for patients
undergoing elective craniotomy [7–11]. This reduction in
anesthetics is clinically important because it achieves early
orientation, less recovery time, and a smooth extubation
without any hypertension during extubation. Moreover
the administration of esmolol allows for the use of any
anesthetic agent in “subanesthetic” doses (<0.5 MAC).
Administration of esmolol before induction in anesthesia
with propofol did not affect BIS suggesting that esmolol
does not modify BIS during general anesthesia. On the
one hand many authors argue that this is the result of the
lack of any substantial sympathetic activation before in-
tubation [19, 20]. On the other hand patients suffering
from a cerebral tumor or even an unruptured aneurysm,
have their sympathetic system already stimulated [21].
In the current study, the mechanism by which esmolol
decreased anesthetic requirements is unknown. Miller
et al. [22] suggested that drugs that affect central cat-
echolamine release might alter anesthetic requirements.
Our results clearly indicate that β-adrenoceptor antago-
nists not only block cardiovascular stress responses after
noxious stimulation, but also increase the antinocicep-
tive component of anesthesia. Esmolol, unlike propran-
olol [23], has no analgesic activity, is believed to have
minimal sedative effects and given its low lipid solubility
does not cross the blood–brain barrier in significant
amounts [20, 24].
One explanation for the action of esmolol on central
antinociceptive mechanism is its propensity to block
β-adrenoceptors. The hemodynamic effects of esmolol
are thought to be mediated by the blockage of periph-
eral, β-adrenergic receptors [25]. B-adrenergic recep-
tors are present in various parts of the reticular
activating system, particularly the medial septal region
of the basal forebrain. Administration of β-adrenergic
receptor agonists in this region elicits enhancement of
behavioral and EEG indices of waking in animals [26].
The low-potency, low-lipid solubility and rapid metab-
olism within the blood stream do not exclude a central
site for esmolol action [27].
Many previous studies have focused on the relation-
ship between perioperative use of β-blocker with opioids.
However, very few have addressed the interaction be-
tween β-blockers and anesthetics agents. Wilson et al,
using esmolol in patients before intubation found that
the propofol requirements for induction of anesthesia
were reduced by 25 %. Based on those findings he sug-
gested that there might be a correlation between re-
duced requirements of propofol and low CO attributed
to the use of esmolol. However, in this study there was
no CO monitoring during esmolol infusion [28]. In an-
other study on patients undergoing non-neurosurgical
procedures, it was shown that high doses of esmolol
(250mcg/kg/min) reduced propofol requirements by 26 %.
The authors proposed that, since there was no evidence of
altered propofol pharmacokinetics, esmolol interacted
with the opioid component in an unspecified manner [29].
Esmolol is thought to suppress the EEG, with a de-
crease in BIS and an increase in the burst suppression
ratio during propofol/alfentanil anesthesia [23]. However
this is in contrast with a recent study reporting that the
blood concentration of propofol necessary to preventing
response to command was unaltered by esmolol. Ac-
cording to Orme et al esmolol may alter drug metabol-
ism and distribution via effects on hepatic blood flow
and subsequent drug clearance [20]. In addition, redistri-
bution of propofol from the central compartment may
be limited and the decreased consumption of anesthetics
may be due to decreased CO and consequently de-
creased hepatic blood flow altering the pharmacokinetic
of propofol [24]. However, this is not in agreement with
our findings that CO was not changed during infusion
Fig. 5 Heart rate fluctuations during perioperative period in the control and esmolol group
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of esmolol. Concurrent with our results is also the one
by Chia et al. [30] reporting that MAP was not different
between groups that received esmolol and those that did
not receive. Thus it seems unlikely that the reduction in
CO is responsible for the low MAC of sevoflurane and
propofol. Moreover, esmolol is metabolized by red blood
cells esterases and not by the liver.
Adequate cerebral blood flow needs adequate global
hemodynamics including blood pressure and CO. The
major concern about esmolol is the possible bradycardia
and low MAP that may occur following its administration.
Regional cerebral oxygen saturation and CO monitoring
by INVOS™ and FloTrac™ closely monitor cerebral perfu-
sion and oxygenation respectively in patients who receive
esmolol. Our results indicate that esmolol infusion did not
produce significant changes in HR or CO, indicating that
esmolol even in the dose of 200mcg/kg/min, is a safe com-
ponent of balanced anesthesia during craniotomies.
Another issue that may arise is that the low dose of an-
esthetics agents used intraoperative might lead to a higher
cerebral metabolic ratio of oxygen (CMRO2). However the
values of rSO2 did not show any reduction that could cor-
relate with inadequate level of anesthesia.
Certain limitations of this study have to be recognized
although we consider that they did not alter the accuracy
of our results. The study population was relatively small,
and we did not use target controlled infusion (TCI) for
calculating the dose of propofol and remifentanil.
Conclusion
Our data revealed that continuous esmolol infusion could
significantly decrease anesthetic requirements during
balanced anesthesia with propofol or sevoflurane and
remifentanil, resulting in successful and uneventful emer-
gence, with no significant changes in heart rate or cardiac
output. B-adrenergic antagonists may represent a novel
class of drugs that can modify anesthetic requirements in
patients undergoing craniotomy and be component of
balanced anesthesia.
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